ADB-FUBHQUCA
Identifiers
  • (S)-N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1,4-dihydroquinoline-3-carboxamide
PubChem CID
Chemical and physical data
FormulaC23H26FN3O2
Molar mass395.478 g·mol−1
3D model (JSmol)
  • NC(=O)[C@@H](NC(=O)C=1Cc2ccccc2N(C=1)Cc1ccc(F)cc1)C(C)(C)C
  • InChI=1S/C23H26FN3O2/c1-23(2,3)20(21(25)28)26-22(29)17-12-16-6-4-5-7-19(16)27(14-17)13-15-8-10-18(24)11-9-15/h4-11,14,20H,12-13H2,1-3H3,(H2,25,28)(H,26,29)
  • Key:WEFDGWANUSMUJL-UHFFFAOYSA-N

ADB-FUBHQUCA is a synthetic cannabinoid receptor agonist that has been sold as a designer drug, first reported in 2022.[1] It is related to the previously reported compound ADB-FUBICA but with the central indole ring system expanded to a 1,4-dihydroquinoline structure. This breaks the aromaticity of the ring system, and ADB-FUBHQUCA is relatively low in potency compared to related compounds where the aromatic core is retained.[2][3][4][5][6][7][8][9][10][11][12][13]

See also

References

  1. ^ "New Substance Report. 118. ADB-FUBHQUCA". AIPSIN monitoring (in Russian). 18 February 2022.
  2. ^ "Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists. A review of the evidence on their use and harms" (PDF). Advisory Council on the Misuse of Drugs. Government Digital Service, UK Government. 2022.
  3. ^ Andrews R, Jorge R, Christie R, Gallegos A (April 2023). "From JWH-018 to OXIZIDS: Structural evolution of synthetic cannabinoids in the European Union from 2008 to present day". Drug Testing and Analysis. 15 (4): 378–387. doi:10.1002/dta.3422. PMID 36507715. S2CID 254610773.
  4. ^ Ferrarini PL, Calderone V, Cavallini T, Manera C, Saccomanni G, Pani L, et al. (April 2004). "Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors". Bioorganic & Medicinal Chemistry. 12 (8): 1921–1933. doi:10.1016/j.bmc.2004.01.035. PMID 15051060.
  5. ^ Stern E, Muccioli GG, Millet R, Goossens JF, Farce A, Chavatte P, et al. (January 2006). "Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling". Journal of Medicinal Chemistry. 49 (1): 70–79. doi:10.1021/jm050467q. PMID 16392793.
  6. ^ Manera C, Benetti V, Castelli MP, Cavallini T, Lazzarotti S, Pibiri F, et al. (October 2006). "Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists". Journal of Medicinal Chemistry. 49 (20): 5947–5957. doi:10.1021/jm0603466. PMID 17004710.
  7. ^ Stern E, Muccioli GG, Bosier B, Hamtiaux L, Millet R, Poupaert JH, et al. (November 2007). "Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality". Journal of Medicinal Chemistry. 50 (22): 5471–5484. doi:10.1021/jm070387h. PMID 17915849.
  8. ^ Manera C, Cascio MG, Benetti V, Allarà M, Tuccinardi T, Martinelli A, et al. (December 2007). "New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists". Bioorganic & Medicinal Chemistry Letters. 17 (23): 6505–6510. doi:10.1016/j.bmcl.2007.09.089. PMID 17942307.
  9. ^ Pasquini S, Botta L, Semeraro T, Mugnaini C, Ligresti A, Palazzo E, et al. (August 2008). "Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo". Journal of Medicinal Chemistry. 51 (16): 5075–5084. doi:10.1021/jm800552f. PMID 18680276.
  10. ^ Manera C, Saccomanni G, Adinolfi B, Benetti V, Ligresti A, Cascio MG, et al. (June 2009). "Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists". Journal of Medicinal Chemistry. 52 (12): 3644–3651. doi:10.1021/jm801563d. PMID 19435366.
  11. ^ Pasquini S, Ligresti A, Mugnaini C, Semeraro T, Cicione L, De Rosa M, et al. (August 2010). "Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands". Journal of Medicinal Chemistry. 53 (16): 5915–5928. doi:10.1021/jm100123x. PMID 20718492.
  12. ^ Pasquini S, De Rosa M, Pedani V, Mugnaini C, Guida F, Luongo L, et al. (August 2011). "Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice". Journal of Medicinal Chemistry. 54 (15): 5444–5453. doi:10.1021/jm200476p. PMID 21702498.
  13. ^ Pasquini S, De Rosa M, Ligresti A, Mugnaini C, Brizzi A, Caradonna NP, et al. (December 2012). "Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors". European Journal of Medicinal Chemistry. 58: 30–43. doi:10.1016/j.ejmech.2012.09.035. PMID 23085772.